Cocrystal Pharma Inc (COCP)

Over the past six months, Cocrystal Pharma's stock has been impacted by several events. In December 2025, the company received Institutional Review Board approval from Emory University School of Medicine to conduct a Phase 1b human challenge study for CDI-988. On March 9, 2026, the first subjects were dosed in its Phase 1b study evaluating CDI-988 for norovirus prevention and treatment. On March 31, 2026, Cocrystal Pharma reported its 2025 financial results and provided updates on its antiviral drug-development programs. On April 2, 2026, the company received FDA Fast Track Designation for CDI-988 for norovirus infection treatment and prevention, leading to a significant positive market reaction. On the same day, a new major risk was identified regarding the company's financial position, indicating less than a year of cash runway. On April 30, 2026, Cocrystal Pharma presented at the 39th International Conference on Antiviral Research (ICAR 2026), highlighting the mechanism of action and clinical advancement of CDI-988. On May 1, 2026, a board change was noted, with an observation of insufficient new directors.

Cocrystal Pharma, Inc. develops antiviral therapeutics for diseases such as influenza and norovirus, which may exhibit seasonality. The demand for its products and services could be higher during peak viral seasons, particularly for respiratory illnesses like influenza, which typically cause outbreaks during the winter months.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases, operating within the Healthcare sector. The company utilizes a proprietary structure-based drug discovery platform to design small-molecule antivirals, primarily focusing on treatments for influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. Key product candidates include CDI-988, an oral pan-viral 3CL protease inhibitor in Phase 1b for norovirus and coronavirus infections; CC-42344, a novel oral PB2 inhibitor for influenza A that has completed a Phase 2a study; and CC-31244, a Hepatitis C virus non-nucleoside inhibitor that has completed Phase 2a clinical trials.

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, with an additional office in Miami, Florida, and a subsidiary, Cocrystal Pharma Australia, Pty LTD, in Melbourne, Australia. Clinical studies have been conducted in locations including Australia and the United Kingdom.

Cocrystal Pharma has maintained a generally positive news sentiment score of 0.78 over the past year, enhanced by increased news coverage and significant milestones in its pipeline development, such as the recent FDA Fast Track designation for CDI-988. However, the company's reputation is closely tied to the success of clinical trials and regulatory milestones, with potential risks including insufficient new directors and having less than a year of cash runway.

The ownership structure of Cocrystal Pharma (COCP) stock includes institutional investors owning approximately 2.31%, insiders owning 45.07%, and public companies and individual investors owning 50.88%. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, Geode Capital Management, Llc, BlackRock, Inc., T3 Companies, LLC, DRW Securities, LLC, Neuberger Berman Group LLC, and State Street Corp. Steven D. Rubin is a significant individual investor.